Search results
Is Editas Medicine Stock a Buy Now?
Motley Fool· 11 months agoInvestors tend to move away from somewhat speculative stocks when the economic going gets rough. Editas Medicine's most advanced candidate is EDIT-301,...
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Motley Fool· 1 year agoEditas Medicine (NASDAQ: EDIT) and Bluebird Bio (NASDAQ: BLUE) are both beaten-down gene-editing...
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
Zacks via Yahoo Finance· 1 year agoFor those looking to find strong Medical stocks, it is prudent to search for companies in the group...
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 weeks agoEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript May 8, 2024 Editas Medicine,...
Where Will Editas Medicine Be in 1 Year?
Motley Fool· 2 years agoGene-editing specialist Editas Medicine (NASDAQ: EDIT) fits the bill, which is why the company's shares have plunged this year. Could this be what's in...
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?
Motley Fool· 1 year agoAfter a tumultuous 2022, growth stocks have started to regain their footing in 2023. Small- and...
Editas Medicine, Inc. (NASDAQ:EDIT) is a favorite amongst institutional investors who own 69%
Simply Wall St. via Yahoo Finance· 6 months agoKey Insights Institutions' substantial holdings in Editas Medicine implies that they have...
2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy It
Motley Fool· 1 year agoThere's a lot of excitement around the potential for gene-editing stocks because their therapies...
Could Editas Medicine Become the Next CRISPR Therapeutics?
Motley Fool via Yahoo Finance· 4 months agoEditas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few...
Editas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 74%...
Simply Wall St. via Yahoo Finance· 1 year agoEvery investor in Editas Medicine, Inc. (NASDAQ:EDIT) should be aware of the most powerful...